FDA pauses Swedish diabetes company's phase III trial plans

The share price of biotech company Diamyd Medical is falling after the the US Food and Drug Administration postponed its planned phase III trial because of several outstanding questions.

Photo: Diamyd Medical / PR

The US Food and Drug Administration (FDA) has put Diamyd Medical's planned phase III trial under a 'partial clinical hold'.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs